WA
GMAB icon

Whipplewood Advisors’s Genmab GMAB Stock Holding History

Whipplewood Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-18
Closed -$372 – 657
2025
Q2 		$372 Sell
18
-148
-89% -$3.04K ﹤0.01% 1141
2025
Q1 		$1.41K Buy
166
+58
+54% +$1.22K ﹤0.01% 954
2024
Q4 		$2.25K Buy
+108
New +$2.37K ﹤0.01% 852

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Whipplewood Advisors's GMAB Position: Q3 2025 in Review

Whipplewood Advisors sold out of Genmab (GMAB) in Q3 2025, closing a stake of 18 shares — an estimated $372 sold.

Whipplewood Advisors first reported a position in GMAB in Q4 2024 and held it in 3 quarters. The position peaked at $2.25K in Q4 2024. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Whipplewood Advisors reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
  • Whipplewood Advisors sold 18 Genmab shares in Q3 2025, an estimated $372.
  • Whipplewood Advisors first reported a position in Genmab in Q4 2024 and held it in 3 quarters.
  • Whipplewood Advisors's Genmab position peaked at $2.25K in Q4 2024.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Whipplewood Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.